Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN FORTE: Semaglutide 2.0 mg vs 1.0 mg in Type 2 Diabetes
NCT03989232Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03989232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989232.